Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Non Operating Income: 2022-2025

Historic Non Operating Income for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $3.6 million.

  • Entrada Therapeutics' Non Operating Income fell 38.07% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $19.5 million for FY2024, which is 27.97% up from last year.
  • Entrada Therapeutics' Non Operating Income amounted to $3.6 million in Q3 2025, which was down 9.00% from $3.9 million recorded in Q2 2025.
  • Entrada Therapeutics' Non Operating Income's 5-year high stood at $5.8 million during Q3 2024, with a 5-year trough of $403,000 in Q2 2022.
  • For the 3-year period, Entrada Therapeutics' Non Operating Income averaged around $4.2 million, with its median value being $4.2 million (2023).
  • Its Non Operating Income has fluctuated over the past 5 years, first surged by 946.65% in 2023, then slumped by 38.07% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Non Operating Income stood at $950,000 in 2022, then skyrocketed by 351.79% to $4.3 million in 2023, then climbed by 19.48% to $5.1 million in 2024, then plummeted by 38.07% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.9 million for Q2 2025, and $4.4 million during Q1 2025.